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T HE use of infusion solutions containing artificial col-loids, especially hydroxyethyl starch (HES), has almost 
declined to zero in critical care patients worldwide due to 
their potential nephrotoxic side effects and increased mortal-
ity, as shown in some studies.1,2 The conclusions drawn from 
these trials were highly controversial. Criticisms included the 
HES preparations used, as well as the initial volume therapy 
before random assignment of these patients.3,4 Some authors 
argued that HES was not applied according to an adequate 
dosage and indication, and therefore is still a safe volume 
expander, whereas other authors concluded that HES should 
be banned generally.5,6 Some recent randomized controlled 
trials found no evidence for nephrotoxicity of artificial col-
loids when used in a perioperative setting in noncritically ill 
patients.7,8 Regardless of potential differences between criti-
cally ill and otherwise healthy intraoperative patients, the 
use of artificial colloids also declined in the operative setting 
during the past years.
Under the conditions of a severe acute blood loss, sub-
stitution by a threefold volume of lactated Ringer’s solution 
is not sufficient to maintain intravascular normovolemia.9 
Instead, highly positive fluid balances are regularly needed. 
To overcome excessively positive fluid balances, colloids 
What We Already Know about This Topic
•  Hydroxyethyl starch causes renal injury when given in high 
doses over prolonged periods to critically ill patients.
•  Whether starches cause more renal toxicity than albumin in 
perioperative patients remains unclear.
What This Article Tells Us That Is New
•  One hundred surgical patients were randomly assigned to 
hydroxyethyl starch (130 kilodaltons) or albumin.
•  The primary endpoint was the change in cystatin C on 
postoperative day 90. Secondary endpoints were estimated 
glomerular filtration rate and serum neutrophil gelatinase-
associated lipocalin until postoperative day 3 and risk, 
injury, failure, loss, and end-stage renal disease criteria up to 
postoperative day 90.
•  There were no significant differences in any outcome, suggesting 
that starches do not cause more renal injury than albumin.
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ABSTRACT
Background: The use of artificial colloids has declined in critical care, whereas they are still used in perioperative medicine. 
Little is known about the nephrotoxic potential in noncritically ill patients during routine surgery. The objective of this trial was 
to evaluate the influences of albumin 5% and balanced hydroxyethyl starch 6% (130/0.4) on renal function and kidney injury.
Methods: One hundred urologic patients undergoing elective cystectomy were randomly assigned for this prospective, single-
blinded, controlled study with two parallel groups to receive either albumin 5% or balanced hydroxyethyl starch 6% (130/0.4) as 
the only perioperative colloid. The primary endpoint was the ratio of serum cystatin C between the last visit at day 90 and the first 
preoperative visit. Secondary endpoints were estimated glomerular filtration rate and serum neutrophil gelatinase-associated lipocalin 
until the third postoperative day and risk, injury, failure, loss, and end-stage renal disease criteria at postoperative days 3 and 90.
Results: The median cystatin C ratio was 1.11 (interquartile range, 1.01 to 1.23) in the albumin and 1.08 (interquartile range, 
1.00 to 1.20) in the hydroxyethyl starch group (median difference = 0.03; 95% CI, –0.09 to 0.08; P = 0.165). Also, there were 
no significant differences concerning serum cystatin C concentrations; estimated glomerular filtration rate; risk, injury, failure, 
loss, and end-stage renal disease criteria; and neutrophil gelatinase-associated lipocalin. Infusion requirements, transfusion 
rates, and perioperative hemodynamics were similar in both groups.
Conclusions:  With respect to renal function and kidney injury, this study indicates that albumin 5% and balanced hydroxy-
ethyl starch 6% have comparable safety profiles in noncritically ill patients undergoing major surgery.  (Anesthesiology 
2018; 128:67-78)
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persist as an important tool for maintaining hemodynamic 
stability in otherwise unstable patients.10,11 Nevertheless, the 
current recommendations for substitution rely on a crystal-
loid–based stage concept for volume therapy.12 This includes 
the recommendation that only blood losses exceeding 20% 
of the patient’s blood volume be treated with colloid solu-
tions, addressing the fact that HES may only be used if 
blood loss cannot be treated by crystalloids alone. From a 
pathophysiological point of view, however, replacement of 
blood and protein losses with colloids in a ratio of 1:1 would 
be more useful and probably beneficial concerning patient 
outcomes.13 A possible alternative to artificial colloids in this 
setting could be albumin. The safety of albumin in intensive 
care medicine was investigated and confirmed in a large trial 
in 2004.14 Until now, however, there were insufficient data 
published investigating the superiority of albumin over HES 
on renal safety in perioperative patients.
To measure potential nephrotoxic side effects of colloids, 
routine laboratory parameters such as creatinine, blood urea 
nitrogen, or the estimated glomerular filtration rate were 
used in most of the previous trials.2,15 Although serum creat-
inine and the glomerular filtration rate (GFR) calculated by 
the Cockroft–Gault formula are of limited value in patients 
with only minor changes in renal function, cystatin C is a 
highly sensitive parameter for detecting early kidney injury 
independent from race, sex, or comorbidities.16–18
We therefore designed a prospective, randomized, single-
blinded trial in a perioperative setting with noncritically ill 
patients to compare the balanced HES 6% (130/0.4) with 
5% albumin. The primary endpoint was the ratio of serum 
cystatin C within an observation period of 90 days.
Materials and Methods
The study was planned as a single-center, single-blinded, 
prospective randomized trial with two parallel groups (ran-
domization ratio 1:1) to compare albumin 5% (study drug) 
and balanced 6% HES 130/0.4 (Volulyte, Fresenius Kabi, 
Germany; comparator). Ethical approvals were obtained 
from the ethics committee of the Ludwig-Maximilians-
University of Munich (Munich, Germany; reference No. 
311-11) and the responsible drug administration authority 
(Paul-Ehrlich-Institute of the German Federal Ministry of 
Health, Langen, Germany). The study was registered at the 
European Medical Association (Brussels, Belgium; EudraCT 
No. 2010-018343-34; registration: July 26, 2011). The trial 
was conducted from May 2012 to May 2015 at the Hospi-
tal of the University of Munich (Munich, Germany). The 
authors prepared this study report in accordance with the 
Consolidated Standards of Reporting Trials guidelines.19 The 
trial was conducted in accordance with the original protocol 
published in 2015.20
Study Participants
After screening and obtaining written informed consent, 
adult patients from 18 to 85 yr with American Society of 
Anesthesiologists (ASA) physical status classifications I to 
IV scheduled for surgical cystectomy were eligible for this 
prospective randomized trial. All of the patients experi-
enced cancer of the urinary tract and were planned either 
to receive an ileum conduit or a neobladder by the institu-
tional urologists. Eligible patients were provided an infor-
mation form describing the trial in detail. Exclusion criteria 
included unfavorable prognosis (e.g., palliative surgical care 
in cases of obstruction of the efferent urinary tract), evidence 
of metastatic disease, coagulopathy or platelet dysfunction, 
preoperative creatinine clearance less than 30 ml/min, pre-
operative chemotherapy with a nephrotoxic drug (e.g., cis-
platin), application of colloidal infusion solutions within 
the past 24 h before surgery, history of hypersensitivity to 
one of the investigational drugs, abuse of drugs or alcohol, 
simultaneous participation in another clinical trial, current 
pregnancy or nursing women, and women of childbearing 
potential without reliable methods of contraception for the 
entire study duration.
Preoperative Care
After inclusion into the clinical trial and informed consent, 
all of the patients were interviewed using a standardized ques-
tionnaire to detect coagulopathies. In addition to routine 
preoperative laboratory parameters (creatinine, C-reactive 
protein, hemoglobin, platelet and leukocyte counts, pro-
thrombin time, and partial thromboplastin time), the serum 
cystatin C concentrations were measured. The use of colloids 
before the surgical intervention was prohibited.
Intraoperative and Postoperative Care
All of the patients received general anesthesia, usually 
combined with a thoracic epidural anesthesia. In case of a 
contraindication to neuraxial block, postoperative patient-
controlled analgesia was started in the recovery room. The 
anesthetic technique was standardized for all of the patients. 
For epidural analgesia, ropivacaine 0.2% in combination 
with epidural sufentanil was used. General anesthesia was 
induced with propofol (2.0 mg/kg), sufentanil (0.4 µg/kg), 
and rocuronium (0.6 mg/kg) and maintained with propo-
fol (5 mg · kg-1 · h-1) or sevoflurane (0.8 to 1.0 minimum 
alveolar concentration; fresh gas flow rate 1 to 2 l/min) in 
combination with remifentanil (0.1 µg · kg-1 · min-1 each). 
Standard monitoring (electrocardiogram, pulsoxymetry, 
temperature, and noninvasive blood pressure) was applied 
in all patients. This was combined with invasive blood pres-
sure measurement via a radial artery. In addition, all of 
the patients received a central venous catheter for applica-
tion of vasopressors or catecholamines if needed. Advanced 
hemodynamic monitoring was performed using the Vigileo 
Monitor with FloTrack-Sensor (Edwards Lifesciences Cor-
poration, USA) until transfer to the ward. During anes-
thesia, all of the clinical parameters and medications were 
recorded by online documentation software (NarkoData, 
IMESO GmbH, Germany).
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The perioperative application of infusion solutions, vasoac-
tive drugs, and blood transfusions was subject to a goal directed 
protocol (see table A, Supplemental Digital Content, http://
links.lww.com/ALN/B548), which is a protocol including 
hemodynamic target parameters and recommendations for 
fluid therapy, vasopressors, catecholamines, and erythrocyte 
transfusion). This protocol was part of the patient file and was 
available to the attending physicians at any time. Deviations 
from the protocol were allowed. Cell-free fluid losses (urine 
output and perspiratio insensibilis up to 500 ml) were replaced 
with a balanced acetated Ringer’s solution in a 1:1 ratio. Blood 
loss was replaced by either albumin 5% or HES 6% (130/0.4) 
in a 1:1 ratio until a specific transfusion trigger was reached or 
to a maximum volume of 30 ml · kg-1 · day-1. The additional 
use of colloidal infusion solutions between postoperative days 
4 and 90 was prohibited by protocol.
After surgery, all of the patients were transferred to the 
recovery room and from there, after being evaluated by the 
attending anesthetist, assigned either to the intensive care 
unit for closely surveyed recovery or to the regular ward, 
where they stayed until discharge from the hospital. Postop-
erative pain management was achieved by patient-controlled 
epidural anesthesia. In case of contraindications for or failure 
of epidural block, patient-controlled analgesia with piritra-
mide was retained for at least 3 days. All of the patients were 
visited by one of the investigators 2 to 4 h after surgery and 
on postoperative days 1 and 3.
Laboratory Parameters and GFR Estimation
Laboratory parameters were obtained before, during, and 
after the surgical intervention. Cystatin C concentration, as 
a parameter for GFR,21 was measured preoperatively; at the 
end of the surgical procedure; and on postoperative days 1, 
3, and 90 using a turbidimetric immunoassay (range, 0.1 to 
10.0 mg/l; reference range, 0.61 to 1.11 mg/l; variation coef-
ficient, 1.83% at 0.83 mg/l and 0.96% at 4.06 mg/l; Biomed 
Diagnostics GmbH, Germany) with a stand-alone analyzer 
(AU 5800; Beckman Coulter GmbH, Germany). Measure-
ments were done once, if values were within range of the 
assay. A total of 9 ml whole blood was withdrawn for each 
determination, immediately centrifuged (3,500 U/min for 
10 min) and stored at –70°C. Serum neutrophil gelatinase-
associated lipocalin, a marker of tubular injury, was mea-
sured after anesthesia induction, at the end of the surgical 
procedure, 2 to 4 h postoperatively, and on postoperative 
days 1 and 3 using the NGAL ELISA kit 036 (Bioporto 
Diagnostics, Denmark).22 All of the other parameters were 
measured by routine laboratory tests. The laboratory staff 
was blinded to the both treatment groups. GFR was esti-
mated using serum cystatin C: estimated GFR (ml · kg-1 · 
1.73 m-2) = 130 × cystatin C–1,069 × age–0.117 – 7.16
Follow-up
All of the patients received a telephone call and were inter-
viewed using a standardized questionnaire on postoperative 
day 90 after surgery. In this interview they were specifically 
asked for additional hospital stays after discharge from the 
primary hospital, potential adverse events, therapy with col-
loids after discharge, and incidence of pruritus.
Outcome Measures
The aim of the study was to detect a possible superiority 
of albumin 5% over HES 6% (130/0.4) by measuring the 
serum cystatin C ratio between postoperative day 90 and pre-
operative values. These differences were regarded as primary 
outcome parameters. Secondary outcome parameters were as 
follows: (1) estimated GFR; (2) serum neutrophil gelatinase-
associated lipocalin as a parameter for kidney injury; and (3) 
risk, injury, failure, loss, and end-stage renal disease (RIFLE) 
criteria at postoperative days 3 and 90. Additional parameters 
were change of serum cystatin C levels over time, crystalloid 
and colloid requirements, transfusion rates, and need for 
vasopressors and catecholamines up to postoperative day 3.
Statistics
Sample Size Estimation. The study was designed with an 
intention-to-treat approach to detect a difference in serum 
cystatin C translating into a 20% decrease of the GFR for the 
HES group compared with the human albumin group, which 
was considered a clinically relevant change (two-sided Mann–
Whitney U test, α level of 0.05, power of 0.8). We calculated a 
sample size of 47 per group to be required. Based on previous 
experience, we estimated the dropout rate to be approximately 
10%. To compensate for these dropouts and slight imbalances 
in the allocation rates to the treatment groups, we planned to 
enroll 105 patients in total (50 to 55 per treatment group).
Randomization
Open-label randomization was performed in a ratio of 
1:1 using randomized balanced blocks with random block 
lengths using a proprietary Web-based randomization tool 
(Randoulette). The procedure considered stratification by 
type of surgical procedure (ileum conduit or neobladder). 
The allocation sequence was generated by a study statisti-
cian. Evaluation of the eligibility, obtaining informed con-
sent, and enrollment of participants were accomplished by a 
research assistant who was registered as a study investigator.
Statistical Methods
All of the analyses were based on the intention-to-treat 
principle. The variables were described using appropri-
ate measures of location and dispersion. Before statis-
tical analysis, the data analyst was blinded for the two 
groups. The primary efficacy analysis of cystatin C changes 
between baseline and day 90 relied on a confirmatory two-
sided Mann–Whitney U test on an α level of 0.05. In 
cases of missing cystatin C values at day 90 (11 patients 
in the albumin group and 4 patients in the HES group), 
we imputed a value greater than the observed cystatin C 
ratios, ensuring that these patients entered the analysis with 
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the highest, that is, most pessimistic ranks for the U test. 
All of the other tests should be regarded as exploratory in 
nature. The 95% confidence limits for the median differ-
ence were based on a quantile regression analysis using the 
SAS QUANTREG procedure (SAS Institute Inc., USA). 
Secondary outcomes were analyzed using Mann–Whitney 
U tests in case of metrical analysis variables and Fisher 
two-sided exact test for dichotomous variables. Due to 
the exploratory nature of these analyses, we did not adjust 
the α level for multiple testing, comparing the resulting 
P values with the local α level of 0.05. Serum cystatin C 
and neutrophil gelatinase-associated lipocalin changes over 
time were analyzed by means of random intercept models 
using the SAS GLIMMIX procedure (SAS Institute Inc.). 
Post hoc tests were adjusted using the Bonferroni method.23 
Safety parameters were analyzed descriptively. Subgroups 
and additional variables that were not specified as primary 
or secondary endpoints were considered by post hoc analy-
sis. All of the analyses were performed using SAS version 
9.3 for Linux (SAS Institute Inc.) and SPSS statistics ver-
sion 23 for Windows (IBM Corporation, USA).
Data Safety Monitoring Board and Interim Analysis
In June 2013 the European Medicines Agency Pharma-
covigilance Risk Assessment Committee (London, United 
Kingdom) concluded, after a review of available evidence, 
that the benefits of infusion solutions containing HES 
would no longer outweigh their risks and therefore recom-
mended completely stopping the administration of HES 
and suspending the marketing authorization.24 Of course, 
these recommendations were also of concern for the ongo-
ing study. Recruitment of new patients had to be paused 
from June 2013. An independent data safety monitoring 
board was established to assess the progress of the study 
and the safety data. Between June 2013 and March 2014, 
the Pharmacovigilance Risk Assessment Committee rec-
ommendations were in part revised by the European Med-
icines Agency and the Coordination Group for Mutual 
Recognition and Decentralized Procedures–Human (Fed-
eral Institute for Drugs and Medical Device, Bonn, Ger-
many). The use of HESs remained prohibited in patients 
with sepsis, burn injuries, or those who were critically ill 
but was now reauthorized in patients with hypovolemia 
caused by acute (sudden) blood loss.25,26 After consider-
ation of these new recommendations, the study was con-
tinued in February 2014. A previously planned interim 
inspection of the date was to be performed in midcourse 
to check the assumptions of our initial sample size calcula-
tion and to allow for a reestimation based on the principle 
of conditional rejection probabilities if necessary.27,28 The 
conditional rejection probabilities principle allows sample 
size reestimation without formal testing and thus with-
out α spending and without the necessity of correcting 
the α level. No statistical adjustments were done after the 
interim inspection.
Results
A total of 131 patients were screened for participation, of 
whom 31 had to be excluded (14 patients declined, 2 with-
drew consent, 14 met exclusion criteria, and 1 was excluded 
for other reasons). A total of 100 patients were randomly 
assigned (albumin: n = 53, HES: n = 47). The participant 
flow diagram is shown in figure 1. All of the patients received 
a radical cystectomy with either construction of a neobladder 
(n = 50) or an ileum conduit (n = 50). The demographic data 
of participants were similar in both groups without any sig-
nificant differences (table 1). None of the patients received 
a colloid infusion before surgical intervention or after the 
first postoperative day. The mean volume of crystalloid infu-
sion given until the third postoperative day was comparable 
in both groups, whereas in the direct perioperative period 
(until postoperative day 1), significantly more crystalloids 
were administered in the albumin group (P = 0.042). The 
average volume of perioperative colloid infusion until post-
operative day 1 was higher in the HES group than in the 
albumin group (P = 0.026). Unfortunately, one patient in 
the HES group accidentally received 100 ml albumin 20% 
in the recovery room, and two patients of the HES group 
received 100 ml, respectively 200 ml of albumin 20% at 
postoperative day 1. Also, two patients in the albumin group 
accidentally received 500 ml HES solution at postoperative 
day 1. The intraoperative transfusion rates for erythrocytes 
and fresh-frozen plasma were not significantly different. All 
of the infusion requirements and transfusion rates are given 
in table 2. Durations of surgery and anesthesia, hemoglobin 
values, hemodynamic variables, and vasoactive medications 
were also comparable between both groups (table 3).
Serum cystatin C concentrations on the day before 
surgery; immediately after the surgical procedure; and on 
postoperative days 1, 3, and 90 showed no significant dif-
ferences between both groups. Accordingly, the GFR values, 
estimated by using the individual serum cystatin C values, 
displayed no significant differences between groups at the 
corresponding time points (fig. 2). With respect to the pri-
mary study endpoint (cystatin C ratio between postoperative 
day 90 and preoperative values), no statistically significant 
difference was observed between groups (albumin group = 
1.11; interquartile range, 1.01 to 1.23; HES group = 1.08; 
interquartile range, 1.00 to 1.20; median difference = 0.03; 
95% CI, –0.09 to 0.08; P = 0.165; table 4).
Concerning intragroup changes, we found significant 
postoperative changes of median serum cystatin C compared 
with their preoperative controls. Cystatin C decreased in both 
groups until postoperative day 3, whereas an increase was 
found between preoperative controls and postoperative day 
90 in the albumin group. After 3 months, cystatin C concen-
trations were measured in 42 patients of the albumin group 
and in 43 patients of the HES group. Of these patients, more 
than 80% in both groups had an estimated GFR decline 
of less than 25% (no acute kidney injury according to the 
RIFLE criteria defined by Bellomo et al.29). The incidences 
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Fig. 1. Participant flow diagram.
Table 1. Demographic Data
 Albumin (N = 53) HES (N = 47) P Value
Ileum conduit/neobladder, n 26/27 24/23 1.000
Sex distribution, n (%)   0.201
  Women 13 (24.5) 6 (12.8)  
  Men 40 (75.5) 41 (87.2)  
Age, yr 70 (61–75) 70 (63–75) 0.435
Height, m 1.76 (1.70–1.81) 1.74 (1.69–1.80) 0.509
Body weight, kg 82 (70–92) 75 (69–90) 0.388
Body mass index, kg/m2 26.7 (24–30) 25.6 (23.6–28.4) 0.464
ASA classification, n (%)   0.054
  I 4 (7.5) 2 (4.3)  
  II 14 (26.4) 24 (51.1)  
  III 34 (64.2) 29 (42.6)  
  IV 1 (1.9) 1 (2.1)  
Metric values are given as median (interquartile range). Mann–Whitney U test was used for metrical variables and Fisher exact test (two-sided) for dichoto-
mous variables.
ASA = American Society of Anesthesiologists; HES = hydroxyethyl starch.
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of stage risk (GFR decrease greater than 25%) and stage 
injury (GFR decrease greater than 50%) at postoperative 
days 3 and 90 were comparable in both groups. Only one 
patient of the albumin group required temporary postopera-
tive renal replacement therapy by hemofiltration. For median 
serum neutrophil gelatinase-associated lipocalin, we found 
no significant intragroup changes in both groups compared 
with preoperative values, as well as no differences between 
the groups. All of the parameters concerning renal function, 
kidney injury, and RIFLE criteria are given in table 4.
Transfer rates to intensive care unit were comparable in 
both groups (albumin group = 47.2%; HES group = 48.9%; 
P = 0.841). In a post hoc analysis comparing intensive care 
and nonintensive care patients in both groups, we found no 
differences regarding serum cystatin C, serum neutrophil 
gelatinase-associated lipocalin, and estimated GFR in the 
postoperative period. Significant differences between inten-
sive care and nonintensive care patients were obtained, that 
is, regarding total colloid requirements (albumin group: 
2,080 ± 971 vs. 1,370 ± 635 ml; P = 0.004; HES group: 
2,308 ± 1,087 vs. 1,678 ± 719 ml; P = 0.038), erythrocyte 
transfusion rate during study period (albumin group: 60% vs. 
25%; P = 0.013; HES group: 62.5% vs. 8.7%; P < 0.0001), 
and need of norepinephrine at postoperative day 1 (albumin 
group: 56% vs. 0%; P < 0.0001; HES group: 54.2% vs. 0%; 
P < 0.0001). In the HES group, total crystalloid requirements 
during postoperative day 3 were significantly higher in inten-
sive care patients compared with nonintensive care patients 
(12,052 ± 2,884 vs. 10,139 ± 2,490 ml; P = 0.019; table 5).
The duration of hospital stay was comparable among 
both groups (HES group: 20 ± 9 days; albumin group: 
22 ± 16 days; P = 0.165). The incidence of pruritus, evalu-
ated by a standardized questionnaire at day 90, was 2.1% 
(n = 1) in the HES group and 15.1% (n = 8) in the albumin 
group (P = 0.014).
Discussion
This prospective, randomized, single-blinded trial with 100 
elective surgical patients analyzed parameters of renal func-
tion and kidney injury. When administered in a perioperative 
setting, no significant differences between albumin 5% and 
Table 2. Infusion Requirements, Blood Loss, and Transfusion Rates
 Albumin (N = 53) HES (N = 47) P Value
Crystalloid requirements, ml    
  Total crystalloid requirements during SP 10,894 ± 2,533 11,116 ± 2,839 0.722
  Until transfer to ICU, PACU, or regular ward 3,328 ± 1,120 2,955 ± 1,043 0.042
  From transfer to POD 1 2,689 ± 1,134 2,912 ± 1,429 0.399
  From POD 1 to 3 4,877 ± 1,706 5,250 ± 1,963 0.429
Colloid requirements, ml*    
  Total colloid requirements during SP 1,705 ± 879 2,000 ± 969 0.082
  Until transfer to ICU, PACU, or regular ward 1,577 ± 684 1,940 ± 828 0.026
  From transfer to POD 1 127 ± 316 60 ± 300 0.185
  From POD 1 to 3 0 ± 0 0 ± 0 1.000
Blood loss and drainage amount, ml    
  Estimated intraoperative blood loss 1,126 ± 549 1,127 ± 618 0.771
  Drainage volume from transfer to POD 1 288 ± 256 222 ± 169 0.261
  Drainage volume from POD 1 to 3 383 ± 432 350 ± 447 0.206
Transfusion rates, n (%)    
  Total transfusion rates during SP    
   Erythrocyte 22 (41.5) 17 (36.2) 0.682
   Fresh-frozen plasma 8 (15.1) 3 (6.4) 0.210
   Platelet 1 (1.9) 0 (0) 1.000
  Intraoperative    
   Erythrocyte 17 (32.1) 11 (23.4) 0.378
   Fresh-frozen plasma 7 (13.2) 3 (6.4) 0.328
   Platelet 0 (0) 0 (0)  
  Until POD 1    
   Erythrocyte 9 (17.0) 8 (17.0) 1.000
   Fresh-frozen plasma 2 (3.8) 0 (0) 0.497
   Platelet 1 (1.9) 0 (0) 1.000
  Until POD 3    
   Erythrocyte 5 (9.4) 4 (8.5) 1.000
   Fresh-frozen plasma 0 (0) 0 (0)  
   Platelet 0 (0) 0 (0)  
Metric values are given as mean ± SD. Mann–Whitney U test was used for metrical variables and Fisher exact test (two-sided) for dichotomous variables.
*Data are shown without erythrocyte, fresh-frozen plasma, and platelet transfusion.
HES = hydroxyethyl starch; ICU = intensive care unit; PACU = postanesthesia care unit; POD = postoperative day; SP = study period. 
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balanced 6% HES solution (130/0.4) were observed regard-
ing cystatin C and estimated GFR in the immediate postop-
erative period until postoperative day 90. Also, no significant 
differences could be detected for serum neutrophil gelatinase-
associated lipocalin up to the third postoperative day.
These results are in good agreement with an investigation 
by Kancir et al.,7 comparing nonbalanced 6% HES solu-
tion (130/0.4) with isotonic saline in 38 patients during hip 
arthroplasty. No harmful renal effects were observed regard-
ing urinary neutrophil gelatinase-associated lipocalin and 
serum creatinine up to postoperative day 12. Bartz et al.30 
examined clinical and renal outcomes of 4,888 postopera-
tive patients after converting from high molecular weight 
(450/0.7) to low molecular weight hetastarch (130/0.4). This 
change resulted in decreased albumin requirements without 
differences in clinical outcomes and mortality. The effects of 
HES 6% (130/0.4) compared with 5% albumin were also 
assessed in a randomized trial in pediatric cardiac surgery 
by van der Linden et al.31 No differences were detected con-
cerning blood loss, transfusion requirements, and renal func-
tion. The authors concluded that HES 6% (130/0.4) was 
equivalent to albumin 5% with regard to volume replace-
ment, thereby extending the data from other trials in adult 
patients.32
In 2011 a meta-analysis by Groeneveld et al.33 of 42 ran-
domized controlled trials including 10,382 patients showed 
Table 3. Duration of Procedures, Hemodynamics, and Vasoactive Medication
 Albumin (N = 53) P Value HES (N = 47) P Value P Value
Duration of surgery, min 225 (183/278)  225 (170/274)  0.421
Duration of anesthesia, min 315 (278/385.5)  312 (263/367)  0.485
Hemoglobin, g/dl      
  Before surgery 12.7 (11.5/14.1)  12.5 (11.1/13.7)  0.641
  After surgery 9.7 (8.8/11)  9.8 (8.4/11)  0.636
  Lowest intraoperative value 9.3 (8.2/10.6)  9.2 (8.1/10.1)  0.548
Cardiac index, l · min-1 · m-2      
  After induction of anesthesia 2.30 (2.10/2.60)  2.32 (2.18/2.52)  1.000*
  After 1 h 2.50 (2.26/2.89) 0.431*† 2.52 (2.22/2.70) 0.066*† 1.000*
  After 2 h 2.60 (2.35/3.00) 0.001*† 2.60 (2.40/3.05) < 0.001*† 1.000*
  At the end of surgery 2.90 (2.59/3.58) < 0.0001*† 2.80 (2.50/3.55) < 0.0001*† 1.000*
Stroke volume variation, %      
  After induction of anesthesia 8 (6/10)  9 (6/12)  1.000*
  After 1 h 10 (7/12) 1.000*† 10 (7/13) 1.000*† 1.000*
  After 2 h 10 (7/13) 0.257*† 9 (6/11) 1.000*† 1.000*
  At the end of surgery 9 (6/12) 1.000*† 9 (7/11) 1.000*† 1.000*
Percentage of time of low MAP during anesthesia 10 (4.5/19)  7 (2/15)  0.363
Lowest MAP during anesthesia, mmHg 54 (45.5/58)  53 (49/58)  0.722
Maximum norepinephrine, µg · kg-1 · min-1      
  Intraoperative 0.14 (0.09/0.21)  0.14 (0.1/0.2)  0.809
  POD 1 0 (0/0.03)  0 (0/0.04)  0.777
  POD 3 0 (0/0)  0 (0/0)  0.573
Need for norepinephrine, n (%)      
  Intraoperative 53 (100)  47 (100)  –
  POD 1 14 (26.4)  13 (27.7)  1.000
  POD 3 4 (7.5)  5 (11.6)  0.731
Need for vasopressin, n (%)      
  Intraoperative 0 (0)  2 (4.2)  0.218
  POD 1 1 (1.9)  1 (2.1)  1.000
  POD 3 0 (0)  1 (2.1)  0.470
Need for epinephrine, n (%)      
  Intraoperative 2 (3.8)  3 (6.4)  0.664
  POD 1 1 (1.9)  2 (4.2)  0.599
  POD 3 0 (0)  1 (2.1)  0.470
Need for dobutamine, n (%)      
  Intraoperative 4 (7.6)  2 (4.2)  0.681
  POD 1 1 (1.9)  0 (0)  1.000
  POD 3 0 (0)  0 (0)  –
Metric values are given as median (interquartile range). Low MAP was defined as less than 70 mmHg for American Society of Anesthesiologists (ASA) III 
and IV patients and less than 60 mmHg for ASA I and II patients. Mann–Whitney U test was used for metrical variables and Fisher exact test (two-sided) 
for dichotomous variables.
*Data show adjusted P values in repeated measurements using Bonferroni correction. †Data show comparison with baseline values.
MAP = mean arterial pressure; POD = postoperative day. 
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a favorable safety profile for albumin compared with HES, 
whereas the available evidence did not support differences 
between the individual HES solutions. However, it is still a 
matter of debate whether older high-molecular-weight HESs 
should be included in meta-analyses or whether compari-
sons should be limited to the recent low-molecular-weight 
forms.34 A meta-analysis by Martin et al.35 included 17 
clinical trials with 1,230 patients and different kinds of sur-
geries. All of the trials compared 6% HES (130/0.4) with 
other colloids or crystalloids. There was no evidence that the 
incidence of renal dysfunction was different. In their review 
analyzing 59 studies with 4,529 patients, van der Linden et 
al.34 evaluated the safety of HES during surgery in noncriti-
cally ill patients. Again, there was no evidence for adverse 
renal effects, nor was tetrastarch followed by increased blood 
loss, transfusion requirement, or mortality. However, most 
included trials used unsuitable comparators like older starch 
solutions or crystalloids. Only a few controlled trials com-
pared HES with albumin. Cystatin C was not assessed in 
these studies, and additional parameters of renal function 
were evaluated in a limited number of patients only. In addi-
tion, some studies were criticized for their too-short observa-
tion periods.36 These shortcomings could limit the clinical 
value of the respective meta-analyses with respect to long-
term renal outcome.36–38
Comparing hetastarch and tetrastarch solutions, Gandhi 
et al.39 demonstrated a comparable plasma volume effect in 
a randomized controlled trial in patients undergoing major 
orthopedic surgery. As primary safety endpoints, the authors 
measured the effects on coagulation by nadirs of factor VIII 
activity and von Willebrand factor activity and were able to 
show a lower effect on coagulation of HES 6% (130/0.4) 
compared with HES 6% (670/0.75). In addition, the totals 
for transfused erythrocytes for those patients requiring trans-
fusion were significant higher.39
A meta-analysis by Jacob et al.40 compared the impact 
of different HES solutions in cardiac surgery. No differ-
ences were found when low-molecular-weight tetrastarch 
(130/0.4) was compared with albumin, gelatine, or crys-
talloid solutions. With respect to safety, the authors were 
unable to identify any disadvantages of tetrastarch. However, 
this meta-analysis was criticized due to a potential bias con-
cerning the included studies, too.41
In the current trial, 38.3% of the patients in the HES 
group and 34.6% in the albumin group had a preoperative 
estimated GFR of less than 60 ml · min-1 · 1.73 m-2 and 
thus met the criteria for chronic kidney disease classified by 
the Kidney Disease Quality Outcome Initiative.42,43 Until 
postoperative day 90, these rates increased to 42.9% (HES 
group) and 53.5% (albumin group). This increase was statis-
tically significant within the albumin group, whereas no sta-
tistical significance was reached between groups. In addition, 
focusing on patients with a preoperative estimated GFR of 
more than 60 ml · min-1 · 1.73 m-2 who developed a chronic 
kidney disease (estimated GFR of 60 ml · min-1 · 1.73 m-2 
or less) until day 90, no statistical difference could be found 
between the groups (table 4). We want to stress that this is a 
result of a post hoc analysis and not a primary or secondary 
study endpoint. The issue of a clinical relevance of this find-
ing should therefore be addressed in future studies.
To assess the nephrotoxic side effects of colloids, routine 
laboratory parameters such as creatinine, estimated GFR, or 
urea, as well as the RIFLE criteria, have been measured in 
many previous trials.2,15 Serum creatinine and the derived 
GFR calculation by the Cockroft–Gault formula are espe-
cially of limited validity in patients with minor decreases 
in renal function. In contrast, Shlipak et al.21 showed that 
serum cystatin C was more sensitive for detecting mild renal 
dysfunction than serum creatinine alone.
The postoperative incidence of pruritus in our patients 
(HES group = 2.1%; albumin group = 15.1%) was low 
compared with previous studies. A subgroup analysis of the 
6S trial in 295 survivors after severe sepsis demonstrated 
pruritus incidences of 49% (HES group) and 43% (Ringer 
group), respectively, without differences between groups.44 
In our study, we observed a significantly higher incidence of 
pruritus in albumin patients. To the best of our knowledge 
there are no data in the literature with respect to this unex-
pected difference, nor are there published pathophysiological 
or histochemical aspects that would provide an explanation. 
Certainly the incidence of pruritus was not evaluated in this 
study preoperatively, and other potential triggers of pruritus 
were present, such as perioperative intravenous or epidural 
opioid administration. Conclusively we do not believe at this 
stage that this reflects a relevant negative effect of albumin.
Our study has some limitations. First, we performed 
a single blinded study, that is, researchers were blinded for 
analysis but clinicians were not. The missing blinding of phy-
sicians, especially regarding the preoperative renal function, 
could have influenced the investigation in some ways that 
would be difficult or impossible to assess. Nevertheless, the 
protocols for administration of both albumin 5% and HES 
6% were identical. Second, power analysis was performed 
Fig. 2. Estimated glomerular filtration rate (eGFR); median 
(interquartile range). HES = hydroxyethyl starch.
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assuming differences in renal function parameters of at least 
20%. Although this number might appear high, it was con-
sidered as a clinically significant outcome. Third, our cohort 
of patients may seem small, but the sample size was deter-
mined by an appropriate power analysis. Also we tried to 
enroll a homogenous study population with patients under-
going cystectomy and a GFR above 30 ml/kg. When analyz-
ing patient characteristics, it turned out that the study groups 
were well comparable with the exception of a nonsignificant 
(P = 0.054) trend toward higher ASA status in the albumin 
group. Comparing ASA III and IV patients in a subgroup 
analysis, we found no significant differences concerning pri-
mary and secondary outcome parameters. Fourth, the aver-
age volume of colloid infusion until transfer to the intensive 
care unit or regular ward was significantly higher in the HES 
group (∆ 363 ml), although hemodynamic parameters were 
comparable in both groups. In contrast, significantly more 
crystalloids (∆ 373 ml) were administered in the albumin 
group during surgical intervention. This can explain why 
there was no difference in hemodynamic variables despite a 
slightly higher colloid supply in the HES group. However, 
volume replacement was triggered by predefined hemody-
namic target parameters. Another possible explanation could 
be the different pharmacokinetics of these two infusion solu-
tions. Both colloids can shift out of the intravascular space, 
whereas HES can be stored in the reticuloendothelial system. 
In contrast to albumin, HES can be eliminated continuously 
via the urine.12,45 The different intravascular half-life of the 
comparators could also explain, at least in part, the differ-
ent fluid requirements. Fifth, we measured serum neutrophil 
gelatinase-associated lipocalin but not urinary neutrophil 
gelatinase-associated lipocalin to assess kidney injury. The 
latter is a more sensitive parameter for glomerular damage. 
The preference of serum determination was due to the surgi-
cal procedure of an ileum conduit in 50% of all cases and, 
hence, the impossibility to collect noncontaminated urinary 
samples. Finally, the subgroup analyses of intensive care ver-
sus nonintensive care patients, as well as the incidences of 
chronic kidney disease, were performed in a post hoc fashion, 
because these had not been defined as primary or secondary 
endpoints. Hence, the respective results should be considered 
with caution and therefore cannot be conclusively assessed.
Table 4. Renal Function and Kidney Injury
 Albumin (N = 53) P Value HES (N = 47) P Value P Value
Cystatin C ratio 1.11 (1.01/1.23)  1.08 (1/1.2)  0.165
Cystatin C ratio intergroup difference 0.03 (95% CI: –0.09 to 0.08)   
Serum cystatin C, mg/l      
  Preoperative 1.02 (0.82/1.44)  1.02 (0.83/1.36)  1.000*
  After surgery 0.85 (0.7/1.11) < 0.0001*† 0.78 (0.65/1.11) < 0.0001*† 1.000*
  POD 1 0.91 (0.75/1.12) 0.0002*† 0.94 (0.75/1.14) 0.1066*† 1.000*
  POD 3 0.82 (0.66/1.15) < 0.0001*† 0.82 (0.69/1.06) 0.0001*† 1.000*
  POD 90 1.23 (1/1.53) < 0.0001*† 1.13 (0.94/1.39) 1.000*† 0.885*
eGFR decrease until POD 90, % 11.46  8.96  0.792
Patients with preoperative CKD, n/N (%) 18/52 (34.6)  18/47 (38.3)  0.835
Patients with CKD at POD 90, n/N (%) 23/43 (53.5) 0.020† 18/42 (42.9) 0.180† 0.388
Patients changing to CKD until POD 90, n/N (%) 8/42 (19.1)  4/43 (9.3)  0.228
Serum NGAL, ng/ml n = 52  n = 47   
  Preoperative 194.6 (135.6/266.4)  183.6 (136.2/241.8)  1.000*
  After surgery 230.5 (177.4/354) 0.2773*† 207.4 (152.8/301.8) 1.000*† 1.000*
  2 to 4 h postoperation 215.3 (158.3/326.1) 0.0504*† 207.2 (156/307) 1.000*† 1.000*
  POD 1 208.1 (153.2/318.4) 1.000*† 230.8 (162.2/304) 1.000*† 1.000*
  POD 3 211.7 (145.3/287.3) 1.000*† 176.9 (121.4/247.7) 1.000*† 1.000*
RIFLE stage POD 3, n (%)     1.000
  No AKI 49 (96.1)  47 (100)   
  Risk 2 (1)  0 (0)   
  Injury 2 (1)  0 (0)   
  Failure 0 (0)  0 (0)   
RIFLE stage POD 90, n (%)     0.586
  No AKI 35 (83.3)  38 (88.4)   
  Risk 5 (11.9)  5 (11.6)   
  Injury 2 (4.8)  0 (0)   
  Failure 0 (0)  0 (0)   
Metric values are given as median (interquartile range). Mann–Whitney U test was used for metrical variables and Fisher exact test (two sided) for dichoto-
mous variables.
*Data show adjusted P values in repeated measurements using Bonferroni correction. †Data show comparison with baseline values.
AKI = acute kidney injury; CKD = chronic kidney disease, defined as glomerular filtration rate less than 60 ml · min-1 · 1.73 m-2 according to the National 
Kidney Foundation39; eGFR = estimated glomerular filtration rate; HES = hydroxyethyl starch; NGAL = neutrophil gelatinase-associated lipocalin; POD = 
postoperative day; RIFLE = risk, injury, failure, loss, and end-stage renal disease; SP = study period (preoperative until POD 90). 
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In conclusion, this randomized, controlled, single-center 
trial did not reveal significant differences concerning the 
influences of a balanced 6% HES (130/0.4) or an albumin 
5% solution on global renal function and parameters of kid-
ney injury in noncritical ill patients receiving major surgery. 
Our investigation indicates that perioperative 5% albumin 
Table 5. Comparison of ICU and Non-ICU Patients
 Albumin (N = 53) P Value HES (n = 47) P Value
 
ICU
47.2% (N = 25)
Non-ICU  
52.8% (N = 28)  
ICU
48.9% (N = 24)
Non-ICU  
51.1% (N = 23) 0.841*
Crystalloid requirements, ml       
  Total crystalloid requirements during SP 11,489 ± 2,806 10,363 ± 2,177 0.209 12,052 ± 2884 10,139 ± 2,490 0.019
  Until transfer to ICU, PACU, or regular ward 3,244 ± 1,347 3,404 ± 890 0.247 2,807 ± 793 3,109 ± 1,252 0.567
  From transfer to POD 1 3,071 ± 1,232 2,348 ± 933 0.048 3,346 ± 1,591 2,459 ± 1,097 0.012
  From POD 1 to 3 5,175 ± 1,707 4,611 ± 1,691 0.314 5,900 ± 2,134 4,572 ± 1,534 0.009
Colloid requirements, ml       
  Total colloid requirements during SP 2,080 ± 971 1,370 ± 635 0.004 2,308 ± 1,087 1,678 ± 719 0.038
  Until transfer to ICU, PACU, or regular ward 1,850 ± 692 1,334 ± 588 0.008 2,192 ± 861 1,678 ± 719 0.040
  From transfer to POD 1 230 ± 420 36 ± 131 0.036 117 ± 416 0 ± 0 0.043
  From POD 1 to 3 0 ± 0 0 ± 0 1.000 0 ± 0 0 ± 0 1.000
  Transfusion rates, n (%)       
Total transfusion rates during SP       
  Erythrocyte 15 (60) 7 (25) 0.013 15 (62.5) 2 (8.7) < 0.0001
  Fresh-frozen plasma 8 (32) 0 (0) 0.001 3 (12.5) 0 (0) 0.234
  Platelet 1 (4) 0 (0) 0.472 0 (0) 0 (0) –
Intraoperative       
  Erythrocyte 12 (48) 5 (17.9) 0.037 9 (37.5) 2 (8.7) 0.036
  Fresh-frozen plasma 7 (28) 0 (0) 0.003 3 (12.5) 0 (0) 0.234
  Platelet 0 (0) 0 (0) – 0 (0) 0 (0) –
Until POD 1       
  Erythrocyte 7 (28) 2 (7.1) 0.067 8 (33.3) 0 (0) 0.004
  Fresh-frozen plasma 2 (8) 0 (0) 0.218 0 (0) 0 (0) –
  Platelet 1 (4) 0 (0) 0.472 0 (0) 0 (0) –
Until POD 3       
  Erythrocyte 4 (16) 1 (3.6) 0.176 4 (16.7) 0 (0) 0.109
  Fresh-frozen plasma 0 (0) 0 (0) – 0 (0) 0 (0) –
  Platelet 0 (0) 0 (0) – 0 (0) 0 (0) –
Maximum norepinephrine, µg · kg-1 · min-1       
  Intraoperative 0.18 ± 0.08 0.14 ± 0.07 0.031 0.19 ± 0.1 0.13 ± 0.06 0.057
  POD 1 0.08 ± 0.11 0 ± 0 < 0.0001 0.08 ± 0.1 0 ± 0 < 0.0001
  POD 3 0.01 ± 0.03 0 ± 0 0.259 0.02 ± 0.06 0 ± 0 0.022
Need for norepinephrine, n (%)       
  Intraoperative 25 (100) 28 (100) – 24 (100) 23 (100) –
  POD 1 14 (56) 0 (0) < 0.0001 13 (54.2) 0 (0) < 0.0001
  POD 3 3 (12) 0 (0) 0.218 5 (20.8) 0 (0) 0.050
Need for vasopressin, n (%)       
  Intraoperative 0 (0) 0 (0) – 1 (4.2) 1 (4.3) 1.000
  POD 1 1 (4) 0 (0) 0.472 1 (4.2) 0 (0) 1.000
  POD 3 0 (0) 0 (0) – 1 (4.2) 0 (0) 1.000
Need for epinephrine, n (%)       
  Intraoperative 2 (8) 0 (0) 0.218 1 (4.2) 0 (0) 0.609
  POD 1 1 (4) 0 (0) 0.472 2 (8.3) 0 (0) 0.489
  POD 3 0 (0) 0 (0) – 1 (4.2) 0 (0) 1.000
Need for dobutamine, n (%)       
  Intraoperative 3 (12) 1 (3.6) 0.333 1 (4.2) 1 (4.3) 1.000
  POD 1 1 (4) 0 (0) 0.472 0 (0) 0 (0) –
  POD 3 0 (0) 0 (0) – 0 (0) 0 (0) –
Metric values are given as mean ± SD. Crystalloid requirement is up to POD 3 and colloid requirements without erythrocyte, fresh-frozen plasma, and plate-
let transfusion. Mann–Whitney U test was used for metrical variables and Fisher exact test (two sided) for dichotomous variables.
*Data compare ICU transfer rates in both groups. 
ICU = intensive care unit; PACU = postanesthesia care unit; POD = postoperative day; SP = study period. 
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and balanced 6% HES solutions have comparable safety 
profiles with respect to renal function in these patients.
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